Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults

HIV Infection and Its Association With an Excess Risk of Clinical Fractures

(2014) Daniel Prieto-Alhambra et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life

(2013) Michael T. Yin et al.   AIDS

Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral Therapy Initiation

(2013) P. M. Grant et al.   CLINICAL INFECTIOUS DISEASES

Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls

(2013) Eugènia Negredo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients

(2013) J. L. Casado et al.   OSTEOPOROSIS INTERNATIONAL

Fractures after antiretroviral initiation

(2012) Michael T. Yin et al.   AIDS

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

Incidence of low and high-energy fractures in persons with and without HIV infection

(2011) Ann-Brit E. Hansen et al.   AIDS

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans

(2011) Julie A. Womack et al.   PLoS One

Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045

(2010) Denise L Jacobson et al.   AIDS

http://www.intmedpress.com/journals/avt/abstract.cfm?id=1650&pid=48

(2010) Alessandra Vigan� et al.   ANTIVIRAL THERAPY

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

(2010) Frank A Post et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Peak bone mass from longitudinal data: Implications for the prevalence, pathophysiology, and diagnosis of osteoporosis

(2010) Claudie Berger et al.   JOURNAL OF BONE AND MINERAL RESEARCH

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir

(2009) Marit GA van Vonderen et al.   AIDS

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

(2009) Claudine Duvivier et al.   AIDS

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

(2009) Todd T Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Fracture Prevalence among Human Immunodeficiency Virus (HIV)-InfectedVersusNon-HIV-Infected Patients in a Large U.S. Healthcare System

(2008) Virginia A. Triant et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM